Skip to content

Mescaline: all studies

Page 31 of 97: studies 301 to 310 of 963, newest first. Back to the mescaline overview

Research

Utilizing Psychedelics to Enhance Well-Being: A Systematic Review

Journal of Psychoactive Drugs March 31, 2025 Samuel Thomson, Nikos Thomacos 11 citations

Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic' therapeutic use for mental illness, this review applies the PERMA Theory of Well-Being to systematically examine their role in enhancing well-being in healthy individuals. The final search of five academic databases was conducted on February 4,...

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.

Psychopharmacology March 26, 2025 Laura Ley, Matthias E. Liechti, Anna M Becker et al. 3 citations

Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively. This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience...

PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS

Journal of medical & health sciences review. March 11, 2025 Ahmad Daryani, Muhammad Ali, Usman Ul Haq

Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders including treatment-resistant depression, PTSD, and anxiety. These substances mainly affect the serotonergic receptors that involve the regulation of consciousness, perceptions, and cognition. These unique alterations in brain connectome show the...

Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V February 1, 2025 Octavio E Fandiño, Aaron R J Hutton, Chunyang Zhang et al. 4 citations

Throughout history, psychedelic compounds have been used for religious, spiritual and recreational purposes. A plethora of studies have reported the use of psychedelic compounds in the treatment of various conditions, such as alcoholism, addictions, depressive state to borderline schizophrenia, personality disorder, among other mental disorders. Psychedelic microdosing, a common technique in...

Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.

Expert Review of Neurotherapeutics February 1, 2025 Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri et al. 4 citations

After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during the last two decades. However, the resounding enthusiasm linked to such 'psychedelic renaissance' runs the risk to unduly minimize the possible hazards associated with these compounds, while expanding their alleged benefits to improbable panacea-like...

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction January 30, 2025 Theodore Piper, Francesca Small, Michael Kelleher et al. 27 citations

Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its quality; and to offer recommendations for...

Development of a diagnostic variable number tandem repeat marker and dual TaqMan genotyping assay to distinguish Lophophora species.

International Journal of Legal Medicine 2025 Eun-Mi Hwang, Kyu-Sik Jeong, Seong Yeon Yoo et al. 2 citations

The Lophophora genus of the Cactaceae family includes Lophophora diffusa and Lophophora williamsii, which has traditionally been used as a natural analgesic; however, its use is now under strict regulation worldwide as it contains mescaline, a unique psychotropic agent. Recently, non-medical and illegal distribution and abuse of L. williamsii have increased worldwide; thus, effective species...

DOI: 10.1007/s00414-024-03318-9 (opens in new tab) Full text (opens in new tab) Mescaline Lophophora diffusa Lophophora williamsii Locked nucleic acid +6

Exploring the regulatory framework of psychedelics in the US & Europe.

Asian Journal of Psychiatry December 1, 2024 Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.

Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory...

Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)

Current Psychology November 21, 2024 Jaime Rojas-Hernández, Lucas F Borkel, Domingo Jesús Quintana Hernández et al. 6 citations

Abstract Psychedelic use has increased in the last decade. However, it is unclear whether the cultural background of the consumers exerts any influence. The aim of the present study was to determine the pattern of psychedelic use in Spain and Spanish-speaking populations in South America and compare these consumption patterns to understand the use of these substances in two culturally distinct...

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.

Pharmaceuticals November 5, 2024 Tamara Valdez, Valbhi Patel, Nattaphone Senesombath et al. 4 citations

Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have...